GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cochlear Ltd (FRA:OC5) » Definitions » Valuation Rank

Cochlear (FRA:OC5) Valuation Rank


View and export this data going back to . Start your Free Trial

What is Cochlear Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Cochlear Valuation Rank Related Terms

Thank you for viewing the detailed overview of Cochlear's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Cochlear (FRA:OC5) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cochlear Ltd (FRA:OC5) » Definitions » Valuation Rank
Comparable Companies
ASX:PNV ASX:AVR ASX:4DX ASX:ARX ASX:IPD ASX:EMV ASX:CYC ASX:IMR ASX:NTI ASX:SOM ABT SYK BSX MDT XTER:SHL EW DXCM SZSE:300760 XAMS:PHIA ZBH
Traded in Other Exchanges
CHEOY:USA CHEOF:USA COH:Australia
Address
1 University Avenue, Macquarie University, Sydney, NSW, AUS, 2109
Website
https://www.cochlear.com
Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2020, 49% of revenue came from the Americas, 35% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.